While Dr Reddy#39;s recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug Revlimid while the base US and India business delivered a subpar performance.
Revlimid overdose boosts Dr Reddy#39;s Q3 earnings, but turns brokerages cautious on January 31, 2024 at 3:22 am
